OBJECTIVES: β-trace protein (BTP), also known as lipocalin-type prostaglandin D2 synthase, has shown to regulate glucose and lipid metabolism in vivo. We sought to study the relationship of serum BTP with diabetes and metabolic syndrome (MetS). METHODS: Data on 3136 participants aged ≥20 years of the National Health and Nutrition Examination Survey III were examined. Logistic regression was used to assess the association of BTP with diabetes and MetS. RESULTS: Reduced levels of BTP were associated with diabetes and MetS in age, sex, and race/ethnicity adjusted models. After further multivariable adjustment, BTP levels in quartile 1 remained significantly associated with MetS (odds ratio 2.04 [95% CI 1.14-3.70], Ptrend = 0.003) when compared with quartile 4. Among the five components of MetS, BTP was associated with hypertriglyceridemia (Ptrend < 0.001) but not diabetes (Ptrend = 0.099). CONCLUSION: MetS is associated with a reduced serum level of BTP.
OBJECTIVES: β-trace protein (BTP), also known as lipocalin-type prostaglandin D2 synthase, has shown to regulate glucose and lipid metabolism in vivo. We sought to study the relationship of serum BTP with diabetes and metabolic syndrome (MetS). METHODS: Data on 3136 participants aged ≥20 years of the National Health and Nutrition Examination Survey III were examined. Logistic regression was used to assess the association of BTP with diabetes and MetS. RESULTS: Reduced levels of BTP were associated with diabetes and MetS in age, sex, and race/ethnicity adjusted models. After further multivariable adjustment, BTP levels in quartile 1 remained significantly associated with MetS (odds ratio 2.04 [95% CI 1.14-3.70], Ptrend = 0.003) when compared with quartile 4. Among the five components of MetS, BTP was associated with hypertriglyceridemia (Ptrend < 0.001) but not diabetes (Ptrend = 0.099). CONCLUSION: MetS is associated with a reduced serum level of BTP.
Authors: Marcelo Rodrigues Bacci; Marina Romera Cavallari; Ross Martin de Rozier-Alves; Beatriz da Costa Aguiar Alves; Fernando Luiz Affonso Fonseca Journal: Drug Des Devel Ther Date: 2015-06-22 Impact factor: 4.162